Sugi Predict

Sugi Predict / Compounds / SCHEMBL2356282

SCHEMBL2356282

SCHEMBL2356282

CCCCCC(=O)NC(CS)C(=O)O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NOD1 Q9Y239 7/20 0.66
▸ FAAH O00519 5/20 0.55
▸ MEN1 O00255 1/20 0.55
▸ MAPK1 P28482 1/20 0.55
▸ KMT2A Q03164 1/20 0.55
▸ KDM4E B2RXH2 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ ALOX15 P16050 1/20 0.53
▸ NFKB1 P19838 1/20 0.53
▸ PTGS2 P35354 1/20 0.53
▸ THPO P40225 1/20 0.53
▸ RECQL P46063 1/20 0.53
▸ BLM P54132 1/20 0.53
▸ SMN1; SMN2 Q16637 1/20 0.53
▸ SLC6A5 Q9Y345 2/20 0.52
▸ EPHX2 P34913 2/20 0.49
▸ PLA2G2C Q5R387 1/20 0.49
▸ DNM1 Q05193 1/20 0.49
▸ ACE P12821 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2356288 1.00 NOD1 (0.66) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL2349133 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL21291889 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL2353176 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL2355124 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL25187792 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL16190310 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL2355126 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL1672712 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A
SCHEMBL2349849 0.98 NOD1 (0.69) NOD1FAAHMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1379214-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING SAME L'OREAL, S.A. (FR) 2004-01-14 — — EP claimed
US-20020159962-A1 Hair relaxer compositions comprising at least one hydroxide compound and at least one activating agent, and methods of using the same L'OREAL S.A. (FR) 2002-10-31 — — US claimed
WO-2002067875-A1 HAIR RELAXER COMPOSITIONS COMPRISING AT LEAST ONE HYDROXIDE COMPOUND AND AT LEAST ONE ACTIVATING AGENT, AND METHODS OF USING THE SAME L'OREAL S.A. (FR) 2002-09-06 — — WO claimed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 — — EP claimed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 — — WO claimed
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2025-01-02 — — US disclosed
EP-4433093-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-09-25 — — EP disclosed
CN-118488855-A Solid composition comprising peptide or protein and acylated amino acid 阿道恰公司 2024-08-13 — — CN disclosed
EP-4299057-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2024-01-03 — — EP disclosed
CN-116419750-A Improved pharmaceutical formulations of GLP-1 receptor agonists 西普鲁梅有限公司 2023-07-11 — — CN disclosed
WO-2023084118-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID ADOCIA (FR) 2023-05-19 — — WO disclosed
EP-4180060-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID Adocia (FR) 2023-05-17 — — EP disclosed
WO-1999045973-A1 DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR THE PROCTER & GAMBLE COMPANY (US) 1999-09-16 — — WO disclosed
EP-0301474-B1 NEW CYSTEINE DERIVATIVES HAVING EXPECTORANT ACTIVITY MAGIS FARMACEUTICI S.P.A. (IT) 1993-09-29 — — EP disclosed
EP-0414605-B1 PASTY AQUEOUS PHARMACEUTICAL COMPOSITIONS ROUSSEL-UCLAF (FR) 1993-05-26 — — EP disclosed
EP-0473700-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1992-03-11 — — EP disclosed
US-5091193-A Zinc oxide, phytic acid and an ester of a fatty alcohol as anti-enzyme ROUSSEL UCLAF (FR) 1992-02-25 — — US disclosed
EP-0414605-A1 Pasty aqueous pharmaceutical compositions ROUSSEL-UCLAF (FR) 1991-02-27 — — EP disclosed
US-4992267-A Mixture of alkali metal hydroxide and disulfide reducing agent JOHNSON PRODUCTS CO., INC. (US) 1991-02-12 — — US disclosed
WO-1990014429-A1 AN ENZYME-CATALYZED PROCESS FOR PREPARING N-ACYL AMINO ACIDS AND N-ACYL AMINO ACID AMIDES NOVO NORDISK A/S (DK) 1990-11-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250000948-A1 SOLID COMPOSITIONS COMPRISING A PEPTIDE OR A PROTEIN AND AN ACYLATED AMINO ACID NPPA, BCAT1, ANPEP NOD1 3434/4885FAAH 858/4885MEN1 2101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.